Thursday, Par Pharmaceutical Companies Inc. (PRX) received final approval from the U.S. Food and Drug Administration or FDA for its Abbreviated New Drug Application for nateglinide tablets. Nateglinide is a generic version of Novartis' Starlix. Par will begin shipping the 60mg and 120mg strengths of nateglinide to the trade immediately. Nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes mellitus.
Par Pharmaceutical Companies Inc., through its subsidiary, Par Pharmaceutical Inc. develops, manufactures, and distributes generic and branded pharmaceuticals drugs in the United States.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.